VANTAGEPOINT INVESTMENT ADVISERS LLCVANTAGEPOINT INVESTMENT ADVISERS LLC

Institutional investor · Portfolio as of Q1 2024

Top Holdings7 positions

Checking export access…
Activity:
TLTTLT
ETF

ISHARES TR

2.5M$234M38.7%$91.28-6.57%
8 qtrssince 2022-Q2
Unchanged
0
AGGAGG
ETF

ISHARES TR

1.7M$166.3M27.5%$92.65-3.73%
16 qtrssince 2020-Q2
Unchanged
0
IVVIVV
ETF

ISHARES TR

284,690$149.7M24.8%$390.51+30.47%
16 qtrssince 2020-Q2
Decreased
0
VUGVUG
ETF

VANGUARD INDEX FDS

95,790$33M5.5%$34.90+62.49%
7 qtrssince 2022-Q3
Decreased
0
IWFIWF
ETF

ISHARES TR

39,315$13.3M2.2%$248.00+34.87%
7 qtrssince 2022-Q3
Decreased
0
VTVVTV
ETF

VANGUARD INDEX FDS

36,300$5.9M1.0%$119.29+29.35%
8 qtrssince 2022-Q2
Unchanged
0
IWDIWD
ETF

ISHARES TR

12,300$2.2M0.4%$143.37+20.93%
8 qtrssince 2022-Q2
Decreased
0
$604.4M
AUM
7
Positions
Q1 2024
Filing
HI score · 1.0/5
Quarterly 13F Value Change
+4%Q4'22$573.1M+5%Q1'23$600.2M+10%Q2'23$660.4M-7%Q3'23$613.3M+22%Q4'23$749.8M-19%Q1'24$604.4M
Activity profile
$ moved · Q1'24
New0%Increased0%Decreased84%Exited16%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.6 years
<1Q0%1-4Q0%1-2Y57%2Y+43%

VANTAGEPOINT INVESTMENT ADVISERS LLC manages $604.4M across 7 positions as of Q1 2024. Top holdings: TLT (38.7%), AGG (27.5%), IVV (24.8%). Fund DNA: Steady Compounder. HoldingsIntel Score: 1/5.0.

Q1 2024 Summary

Exited 2, trimmed 4. No standout high-conviction moves this quarter. Portfolio: $604M across 7 positions.

Top holdings by portfolio weight

Total AUM$604M
TLT38.73%
AGG27.52%
IVV24.76%
VUG5.46%
IWF2.19%
VTV0.98%
IWD0.36%
IJH0.00%
IWR0.00%

Portfolio allocation by GICS sector

Sectors1
Unknown100.00%

Behavioral investing profile

Checking access…
Steady Compounder- primarily Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L84
Conviction49
Concentration51
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
4Q
VUGVUGVANGUARD INDEX FDS
Q3 2025 → Q2 2026+6.8M shares+$581.2M
3Q
AVEMAVEMAMERICAN CENTY ETF TR
Q4 2025 → Q2 2026+126,777 shares+$60.7M
2Q
VWOVWOVANGUARD EMERGING MARKETS ETF
Q1 2026 → Q2 2026+521,392 shares+$44.5M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used